Search for a trial

NY-ESO expression testing using Ventana*s IHC test in Daiichi Sankyo*s First-in-human study of DS-2243a in participants with Advanced Solid Tumors

As a primary objective, the performance of NY-ESO (SP511) CTA will be assessed by determining how often the device is able to yield a valid NY-ESO positive result. The corresponding endpoint for this study is the percentage of cases that yield &…